DPYSL4

Across TCGA pan-cancer cohorts, DPYSL4 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DPYSL4 data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher DPYSL4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DPYSL4 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUSC show a favorable association.

OV, ESCA, and UCEC are the cancer types where DPYSL4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.082	0.844	<.001	36	view →
ESCA	OS	Median	II,III,IV	0.136	0.703	<.001	24	view →
UCEC	DFS	Median	All	0.938	0.624	.012	20	view →
LUSC	DFS	Median	All	0.841	0.378	.010	10	view →
SKCM	DFS	Median	All	0.046	0.757	<.001	9	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DPYSL4–OV (OS)

Open the OV breakdown →